Kardigan, Inc.
Clinical trials sponsored by Kardigan, Inc., explained in plain language.
A biopharmaceutical company developing therapies for cardiovascular diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot aims to keep blood pressure in check after hospital discharge Results expected Dec 2026 (estimated)
- New pill aims to strengthen hearts in genetic cardiomyopathy Results expected Sep 2027 (estimated) 🚀 Make-or-break
-
Can a new drug strengthen hearts weakened by genetic disease?
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of an investigational drug called danicamtiv in adults with symptomatic genetic or familial dilated cardiomyopathy (DCM), a condition where the heart muscle weakens and enlarges. Participants who completed a prior 24-week st…
Phase 3 • Sponsor: Kardigan, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New shot aims to keep blood pressure in check after hospital discharge
Disease control Recruiting nowThis study tests a drug called tonlamarsen in adults who were recently hospitalized for dangerously high blood pressure. Participants receive either the drug or a placebo as a shot under the skin every 4 weeks. The goal is to see if tonlamarsen can lower blood pressure and reduce…
Phase 2 • Sponsor: Kardigan, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill aims to strengthen hearts in genetic cardiomyopathy
Disease control Recruiting nowThis study tests an experimental daily pill, danicamtiv, in 332 people with genetic or familial dilated cardiomyopathy (a weakened, enlarged heart). Participants take the drug or a placebo for about 6 months to see if it improves heart function and exercise ability. The goal is t…
Phase 2/3 • Sponsor: Kardigan, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a simple pill delay heart valve surgery?
Disease control Recruiting nowThis study tests whether a daily medication called ataciguat can slow the progression of moderate aortic valve stenosis, a condition where the heart's aortic valve becomes narrowed. About 1,276 adults aged 50 and older will receive either ataciguat or a placebo for up to 3 years.…
Phase 2/3 • Sponsor: Kardigan, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC